The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...

Medicare will soon start paying lower prices for Novo Nordisk’s weight- loss drug Wegovy and its Type 2 diabetes treatment ...

Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs. Updated January 17, 2025 ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet selected for price negotiation, according to a report released Thursday.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers ...

Medicare covers Ozempic for its FDA-approved use to help manage blood sugar levels in people with type 2 diabetes. Ozempic may be used off-label for prediabetes, but that use may not be covered.

Ozempic, Wegovy and other drugs are among 15 selected for Medicare’s price negotiations The price negotiations for the additional 15 drugs selected will be handled by the incoming Trump ...

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

Millions of Americans would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare and Medicaid under a rule the Biden administration has proposed.

Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.